Navigation Links
Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
Date:10/24/2007

BERKELEY HEIGHTS, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that clinical data from the Company's programs for Genasense(R) (oblimersen) in patients with advanced melanoma will be featured at the 4th International Melanoma Congress. The conference will take place at the New York Marriott Financial Center Hotel, New York, NY from November 1-4, 2007. A poster session featuring the Genasense data will take place on Thursday November 1 from 8-10 am EDT.

Titles and authors include the following:

Progression-free survival (PFS) with an oblimersen-dacarbazine regimen in advanced melanoma: PFS difference is not explained by assessment asymmetry. Presenter: E. Gilles.

Overview of the AGENDA Study: A randomized, double-blind study of Genasense plus dacarbazine in chemotherapy-naive patients with advanced melanoma and low LDH. Presenter: A. Bedikian.

A Phase I study of the triple combination of oblimersen, temozolomide, and Abraxane in patients with advanced melanoma and normal LDH. Presenter: A. Pavlick.

Pharmacokinetics of oblimersen in combination with dacarbazine in metastatic melanoma: randomized intra-subject evaluation. Presenter: D. Kerob.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversif
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Restore Health, a leading personalized ... announced that it is now offering pharmacogenetics testing ... individual based upon their particular genetic makeup. Comprehensive ... interaction between a patient,s genetics and their entire ... to provide this new service to healthcare providers ...
(Date:7/24/2014)... 24, 2014  Mettler-Toledo International Inc. (NYSE: ... Provided below are the highlights: , Sales ... compared with the prior year. Reported sales increased 5% ... Net earnings per diluted share as reported (EPS) were ... 2013. Adjusted EPS was $2.57, an increase of 9% ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
(Date:7/25/2014)... According to the new report "Sapphire Technology ... Geography - Analysis & Forecast to 2013 - 2020", ... reach $3.01 Billion by 2020 at a CAGR of ... is expected to reach $6.17 billion by 2020 at ... of application and geography. , Browse more than 65 ...
(Date:7/25/2014)... 2014 Training Mask LLC, is proud ... an endorsement agreement to promote the mask and its’ ... for over 10 years, and ran over 30 ultra ... of the Angeles Crest 100-mile endurance run. Brian is ... of the endurance, strength and conditioning paradigm. He created ...
(Date:7/25/2014)... attack patients could be treated more quickly after ... electrocardiogram (ECG) and blood test on arrival, is ... pain, a new study shows., The findings of ... Emergency Medicine Journal, could potentially make a huge ... pain is the most common reason for emergency ...
(Date:7/25/2014)... 25, 2014 DON’T PAUSE is a popular ... bloating, hot flashes, mood swings, burning tongue menopause ... Shoreh Ershadi. The AntiAging Institute of California is now offering ... women to try this revolutionary product. For a limited time, ... a third bottle at no charge. , Water ...
(Date:7/25/2014)... and desires in initial romantic encounters determine the fate ... those initial "sparks" necessary to fuel sexual desire and ... a desirable trait for both men and women on ... the other person? Do men perceive responsive women as ... women,s perceptions of men? A study published in ...
Breaking Medicine News(10 mins):Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Training Mask LLC Announces the Signing of World-Renowned Coach Brian MacKenzie 2Health News:Training Mask LLC Announces the Signing of World-Renowned Coach Brian MacKenzie 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:AntiAging Institute of California Now Offers DON'T PAUSE for Menopause with a Special Promotion 2Health News:Why do men prefer nice women? 2Health News:Why do men prefer nice women? 3
... health-care workers getting vaccine , TUESDAY, Nov. 3 (HealthDay News) ... doses available and is on track to have another 10 ... Tuesday. , So far, that isn,t enough to prevent long ... officials had projected earlier this week. , "We,re having a ...
... ... (EHR) , ... Scottsdale, AZ (PRWEB) November 3, 2009 -- MxSecure, Inc. , the ... multi-specialty clinics and community health centers, today announced an agreement with HealthCare ...
... ... online selection of plastic card printing to offer PVC materials in addition to traditional ... ... plastic card printing innovations by adding new PVC material options to their plastic card ...
... Nov. 3 , What: ... LoJack Corporation (Nasdaq: LOJN ) has hosted an ... valuable information related to Alzheimer,s including: , The ... day-to-day challenges faced by people with Alzheimer,s and their ...
... 3 WebMD Health Corp. (Nasdaq: WBMD ), ... results for the three months ended September 30, 2009. ... financial and operating performance," said Wayne Gattinella, President and ... environment, WebMD continues to expand its audience, revenue and ...
... the largest nurses, union and professional association in U.S. history ... of the affiliation agreement vote by delegates representing 80 percent ... Even as a number of state affiliates inexplicably failed to ... moved forward to create the 150,000 member RN "Super Union." ...
Cached Medicine News:Health News:CDC Urges Patience As More Swine Flu Shots Arrive 2Health News:Medical Transcription Service Provider, MxSecure, Teams with HealthCare Partners/PACIS to Accelerate Physician EHR Adoption 2Health News:Medical Transcription Service Provider, MxSecure, Teams with HealthCare Partners/PACIS to Accelerate Physician EHR Adoption 3Health News:My1Stop.com Expands Plastic Card Offering to Include PVC Material Choices 2Health News:November is National Alzheimer's Awareness Month 2Health News:WebMD Announces Third Quarter Financial Results 2Health News:WebMD Announces Third Quarter Financial Results 3Health News:WebMD Announces Third Quarter Financial Results 4Health News:WebMD Announces Third Quarter Financial Results 5Health News:WebMD Announces Third Quarter Financial Results 6Health News:WebMD Announces Third Quarter Financial Results 7Health News:WebMD Announces Third Quarter Financial Results 8Health News:WebMD Announces Third Quarter Financial Results 9Health News:WebMD Announces Third Quarter Financial Results 10Health News:WebMD Announces Third Quarter Financial Results 11Health News:WebMD Announces Third Quarter Financial Results 12Health News:WebMD Announces Third Quarter Financial Results 13Health News:WebMD Announces Third Quarter Financial Results 14Health News:WebMD Announces Third Quarter Financial Results 15Health News:WebMD Announces Third Quarter Financial Results 16Health News:WebMD Announces Third Quarter Financial Results 17Health News:WebMD Announces Third Quarter Financial Results 18Health News:WebMD Announces Third Quarter Financial Results 19Health News:WebMD Announces Third Quarter Financial Results 20Health News:WebMD Announces Third Quarter Financial Results 21Health News:WebMD Announces Third Quarter Financial Results 22Health News:WebMD Announces Third Quarter Financial Results 23Health News:United American Nurses Vote Brings 'Super Union' and New Chapter for RN Power Closer to Achievement 2Health News:United American Nurses Vote Brings 'Super Union' and New Chapter for RN Power Closer to Achievement 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: